Pliant Therapeutics (PLRX) FCF Margin (2020 - 2023)
Pliant Therapeutics (PLRX) posted quarterly FCF Margin of 10292.34% for Q2 2023, down 979825.0% year-over-year from N/an in Q2 2022, and down 352.81% quarter-over-quarter from 2272.97% in Q1 2023.
Pliant Therapeutics (PLRX) FCF Margin (2020 - 2023) Analysis & Trends
Pliant Therapeutics (PLRX) has reported FCF Margin for 4 consecutive years, with 10292.34% the latest figure, recorded in Q2 2023.
- In Q2 2023, FCF Margin fell 979825.0% year-over-year to 10292.34%; the TTM figure through Mar 2024 stood at 47289.11% (down 4620880.0% YoY), while the FY2023 annual figure was 7422.91%, down 642765.0% from the prior year.
- FCF Margin retreated to 10292.34% in Q2 2023 per PLRX's latest filing, from 2272.97% in the prior quarter.
- Across five years, FCF Margin topped out at 192.14% in Q2 2020 and bottomed at 10292.34% in Q2 2023.
- Historically, FCF Margin has averaged 1593.63% across 4 years, with a median of 1031.17% in 2021.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 63973 bps — and 2023, when it tumbled 979825 bps.
- Pliant Therapeutics' FCF Margin stood at 386.51% in 2020, then plunged by 140 bps to 928.51% in 2021, then plunged by 81 bps to 1677.66% in 2022, then slumped by 513 bps to 10292.34% in 2023.
- Business Quant data shows PLRX's FCF Margin at 10292.34% in Q2 2023, 2272.97% in Q1 2023, and 1677.66% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -10,292.34% |
| Mar 31, 2023 | -2,272.97% |
| Dec 31, 2022 | -1,677.66% |
| Sep 30, 2022 | -1,189.81% |
| Jun 30, 2022 | -494.09% |
| Mar 31, 2022 | -1,692.71% |
| Dec 31, 2021 | -928.51% |
| Sep 30, 2021 | -1,427.95% |
| Jun 30, 2021 | -1,133.82% |
| Mar 31, 2021 | -628.56% |
| Dec 31, 2020 | -386.51% |
| Sep 30, 2020 | -334.75% |
| Jun 30, 2020 | 192.14% |
| Mar 31, 2020 | -43.31% |